Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
about
Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1.p53-independent p21 induction by MELK inhibition.DEPDC1 is required for cell cycle progression and motility in nasopharyngeal carcinoma.Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.The target landscape of clinical kinase drugs.MELK is a novel therapeutic target in high-risk neuroblastoma.Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.Identification of potential therapeutic targets in prostate cancer through a cross-species approach.Challenges in validating candidate therapeutic targets in cancer.
P2860
Q36289944-1CB744E9-8D24-475F-B582-26D3D974C48EQ38648606-DAE1E92F-4BB8-45E2-B22B-158DE54BAB54Q41085328-5FE7274B-D197-4459-B226-50CB18490100Q41338135-439334A9-97F5-4F51-82DF-08B5D70B3A6DQ41709133-2204C392-33E6-4A02-9E0D-3326372F652DQ42362706-EB6441A5-4A2C-4815-AC2E-8986DBA6A6F2Q47105057-2C2292FA-30F5-4452-8C93-A70D93C0E391Q47345032-363B7388-729C-42F0-BF4D-989725DFC85DQ49187608-DBADAF8C-74CC-4A09-A5C1-39652D83A3D6Q49869942-E70BC977-37DF-44D5-ADF3-20187DB3E766Q50043890-A4C24332-A6FC-46A7-A3BB-7366B06ABC6DQ50123858-DD0E1299-5A07-4006-AD1D-702EA4DCAD3F
P2860
Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Preclinical evaluation of biom ...... or activity of MELK inhibitor.
@en
type
label
Preclinical evaluation of biom ...... or activity of MELK inhibitor.
@en
prefLabel
Preclinical evaluation of biom ...... or activity of MELK inhibitor.
@en
P2093
P2860
P356
P1433
P1476
Preclinical evaluation of biom ...... or activity of MELK inhibitor.
@en
P2093
Akiko Taira
Kyoko Kijima
Naofumi Takamatsu
Suyoun Chung
Takashi Miyamoto
Yoshiko Fujisawa
Yosuke Harada
Yusuke Nakamura
P2860
P304
18171-18182
P356
10.18632/ONCOTARGET.7685
P407
P577
2016-02-24T00:00:00Z